Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Suspected non-Alzheimer disease pathophysiology — concept and controversy
Clifford R. Jack, David S. Knopman, Gaël Chételat, et al.
Nature Reviews Neurology (2016) Vol. 12, Iss. 2, pp. 117-124
Open Access | Times Cited: 266

Showing 1-25 of 266 citing articles:

Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Peter T. Nelson, Dennis W. Dickson, John Q. Trojanowski, et al.
Brain (2019) Vol. 142, Iss. 6, pp. 1503-1527
Open Access | Times Cited: 1157
Ageing, neurodegeneration and brain rejuvenation
Tony Wyss‐Coray
Nature (2016) Vol. 539, Iss. 7628, pp. 180-186
Open Access | Times Cited: 981
Alzheimer’s Disease: Past, Present, and Future
Mark W. Bondi, Emily C. Edmonds, David P. Salmon
Journal of the International Neuropsychological Society (2017) Vol. 23, Iss. 9-10, pp. 818-831
Open Access | Times Cited: 513
Imaging the evolution and pathophysiology of Alzheimer disease
William J. Jagust
Nature reviews. Neuroscience (2018) Vol. 19, Iss. 11, pp. 687-700
Open Access | Times Cited: 467
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 464
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Dallas P. Veitch, Michael W. Weiner, Paul Aisen, et al.
Alzheimer s & Dementia (2018) Vol. 15, Iss. 1, pp. 106-152
Closed Access | Times Cited: 395
Spatial navigation deficits — overlooked cognitive marker for preclinical Alzheimer disease?
Gillian Coughlan, Jan Laczó, Jakub Hort, et al.
Nature Reviews Neurology (2018) Vol. 14, Iss. 8, pp. 496-506
Closed Access | Times Cited: 394
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
Michael W. Weiner, Dallas P. Veitch, Paul Aisen, et al.
Alzheimer s & Dementia (2016) Vol. 13, Iss. 5, pp. 561-571
Open Access | Times Cited: 372
Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
Ron Brookmeyer, Nada Abdalla, Claudia H. Kawas, et al.
Alzheimer s & Dementia (2017) Vol. 14, Iss. 2, pp. 121-129
Open Access | Times Cited: 366
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Michael W. Weiner, Dallas P. Veitch, Paul Aisen, et al.
Alzheimer s & Dementia (2017) Vol. 13, Iss. 4
Open Access | Times Cited: 271
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
Marc Suárez‐Calvet, Estrella Morenas‐Rodríguez, Gernot Kleinberger, et al.
Molecular Neurodegeneration (2019) Vol. 14, Iss. 1
Open Access | Times Cited: 264
Aducanumab: Appropriate Use Recommendations
Joanne Cummings, Paul Aisen, Liana G. Apostolova, et al.
The Journal of Prevention of Alzheimer s Disease (2021), pp. 1-13
Open Access | Times Cited: 226
The “rights” of precision drug development for Alzheimer’s disease
Jeffrey L. Cummings, Howard Feldman, Philip Scheltens
Alzheimer s Research & Therapy (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 203
Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Walter Gulisano, Daniele Maugeri, Marian A. Baltrons, et al.
Journal of Alzheimer s Disease (2018) Vol. 64, Iss. s1, pp. S611-S631
Open Access | Times Cited: 183
Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease
Gary P. Morris, Ian A. Clark, Bryce Vissel
Acta Neuropathologica (2018) Vol. 136, Iss. 5, pp. 663-689
Open Access | Times Cited: 183
Prevention of dementia in an ageing world: Evidence and biological rationale
Giulia Grande, Chengxuan Qiu, Laura Fratiglioni
Ageing Research Reviews (2020) Vol. 64, pp. 101045-101045
Open Access | Times Cited: 170
Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease
Chanchal Sharma, Sehwan Kim, Youngpyo Nam, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4850-4850
Open Access | Times Cited: 146
Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials
Ranjan Duara, Warren Barker
Neurotherapeutics (2022) Vol. 19, Iss. 1, pp. 8-25
Open Access | Times Cited: 74
Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART)
Keith A. Josephs, Melissa E. Murray, Nirubol Tosakulwong, et al.
Acta Neuropathologica (2017) Vol. 133, Iss. 5, pp. 705-715
Open Access | Times Cited: 145
“New Old Pathologies”: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS)
Peter T. Nelson, John Q. Trojanowski, Erin L. Abner, et al.
Journal of Neuropathology & Experimental Neurology (2016) Vol. 75, Iss. 6, pp. 482-498
Open Access | Times Cited: 141
Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease
Akinori Nakamura, Pablo Cuesta, Alberto Fernández, et al.
Brain (2018) Vol. 141, Iss. 5, pp. 1470-1485
Open Access | Times Cited: 134
Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease
Ron Brookmeyer, Nada Abdalla
Alzheimer s & Dementia (2018) Vol. 14, Iss. 8, pp. 981-988
Open Access | Times Cited: 132
Multifactorial causal model of brain (dis)organization and therapeutic intervention: Application to Alzheimer’s disease
Yasser Iturria‐Medina, Félix Carbonell, Roberto C. Sotero, et al.
NeuroImage (2017) Vol. 152, pp. 60-77
Open Access | Times Cited: 125
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
David S. Knopman, Samantha Budd Haeberlein, María C. Carrillo, et al.
Alzheimer s & Dementia (2018) Vol. 14, Iss. 4, pp. 563-575
Open Access | Times Cited: 124
Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies
Ralph N. Martins, Victor L. Villemagne, Hamid R. Sohrabi, et al.
Journal of Alzheimer s Disease (2018) Vol. 62, Iss. 3, pp. 965-992
Open Access | Times Cited: 120
Page 1 - Next Page

Scroll to top